ClinicalTrials.gg
CompletedNCT07359833Updated Jan 22, 2026

Oxygen Reserve Index Guided FiO₂ Titration in One-Lung Ventilation

An interventional study of Oxygen Reserve Index (ORi)-guided oxygen titration in One Lung Ventilation in Thoracic Surgery, sponsored by Gazi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Gazi University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.
  • Registered 3 years 5 months after the study started (first participant enrolled Aug 2022, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

One-lung ventilation (OLV) is routinely used during thoracic surgery to facilitate surgical exposure but is associated with an increased risk of intraoperative hypoxemia. To prevent hypoxia, high fractions of inspired oxygen (FiO₂) are commonly administered; however, excessive oxygen delivery may lead to hyperoxia and oxidative tissue injury. The Oxygen Reserve Index (ORi) is a novel, noninvasive monitoring parameter that provides real-time information on moderate hyperoxia and may allow more precise titration of FiO₂ during anesthesia.

The aim of this prospective, randomized clinical trial is to evaluate whether ORi-guided intraoperative oxygen management can reduce oxygen exposure during OLV without increasing hypoxemia and to assess its effects on oxidative stress biomarkers and postoperative outcomes. Adult patients undergoing elective thoracic surgery with OLV are randomized to receive either ORi-guided FiO₂ titration or conventional oxygen management. Oxidative stress biomarkers and postoperative pulmonary complications are compared between groups.

Read the detailed description

One-lung ventilation is an essential component of thoracic anesthesia but poses significant challenges in maintaining adequate oxygenation. In clinical practice, high FiO₂ levels are often applied to prevent hypoxemia; however, prolonged exposure to hyperoxia has been associated with increased oxidative stress, inflammatory responses, and potential tissue damage. Despite growing awareness of oxygen toxicity, optimal intraoperative oxygen titration strategies during OLV remain poorly defined.

The Oxygen Reserve Index is derived from multiwavelength pulse oximetry and provides continuous, noninvasive information on moderate hyperoxia (corresponding to arterial oxygen tensions above normoxia but below severe hyperoxia). ORi monitoring may enable anesthesiologists to titrate FiO₂ more precisely, thereby avoiding unnecessary oxygen exposure while maintaining adequate oxygenation.

In this prospective, randomized clinical trial, adult patients scheduled for elective thoracic surgery requiring OLV are allocated to either an ORi-monitored group or a control group. In the ORi group, FiO₂ is adjusted intraoperatively according to predefined ORi thresholds, whereas in the control group FiO₂ is managed according to standard clinical practice based on pulse oximetry. Blood and tracheal aspirate samples are collected preoperatively and at predefined postoperative time points to measure interleukin-6, superoxide dismutase, and malondialdehyde levels as markers of inflammation and oxidative stress. Postoperative pulmonary complications and surgical site infections are recorded during intensive care unit and ward follow-up.

This study aims to determine whether ORi-guided oxygen titration during OLV can safely reduce intraoperative oxygen exposure and to clarify its impact on biochemical markers of oxidative stress and clinical outcomes such as postoperative pulmonary complications and surgical site infection.

02

Conditions studied

  • One Lung Ventilation in Thoracic Surgery

Browse trials for

Keywords

  • One-Lung Ventilation
  • oxygen reserve index
  • Hyperoxia
  • Thoracic surgery
  • Oxidative stress
  • Oxygen
03

In context

Hyperoxia

115 studies on the registry are indexed under Hyperoxia; 13 are open to participants now.

This study's enrollment of 60 is above the median of 48 across 82 interventional studies indexed under Hyperoxia.

Browse Hyperoxia studies →

Lead sponsor

Gazi University is the lead sponsor of 551 studies on the registry; 102 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age between 18-85 years Elective case Thoracic surgeries performed with one-lung ventilation using a double-lumen endotracheal tube Left ventricule (LVEF)>45%

Exclusion criteria

Exclusion Criteria:

  • heart failure () \< 45% severe valvular disease admission as an emergency case history of prior lung resection presence of peripheral arterial disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ORi group.

    In this group, intraoperative FiO₂ was titrated according to predefined Oxygen Reserve Index (ORi) thresholds during one-lung ventilation and all intraoperative period, with the aim of maintaining adequate oxygenation while avoiding unnecessary hyperoxia.

    Device: Oxygen Reserve Index (ORi)-guided oxygen titration

  • No intervention
    Non-ORi group

    In this group, intraoperative FiO₂ was adjusted based solely on pulse oximetry (SpO₂) monitoring, without the use of Oxygen Reserve Index (ORi) guidance.

Interventions

  • DeviceOxygen Reserve Index (ORi)-guided oxygen titration

    FiO₂ adjusted intraoperatively according to predefined ORi thresholds during thoracic surgery and one lung ventilation period.

06

What researchers measure

Primary outcomes

  1. Mean intraoperative FiO₂

    The primary outcome is the mean fraction of inspired oxygen (FiO₂) administered during one-lung ventilation and throughout the entire duration of surgery, recorded continuously intraoperatively and compared between the ORi-guided and conventional oxygen management groups.

    Time frame: From anesthesia induction to the extubation

Secondary outcomes

  1. Oxidative stress biomarkers (IL-6, SOD, MDA)

    Changes in serum and tracheal aspirate levels of interleukin-6, superoxide dismutase, and malondialdehyde assessed at four time points. Serum biomarker levels are measured at anesthesia induction and at the 12th and 24th postoperative hours, while tracheal aspirate biomarker levels are measured at extubation. Results are compared between the ORi and Non-ORİ groups.

    Time frame: Anesthesia induction, extubation, postoperative 12th hour, postoperative 24th hour

  2. Postoperative pulmonary complications

    Incidence of postoperative pulmonary complications, including prolonged drainage, hemothorax, bronchopleural fistula, reintubation, atelectasis, bronchopneumonia, and acute respiratory distress syndrome, assessed during intensive care unit and ward follow-up.

    Time frame: up to 2 weeks

  3. Surgical site infections

    Incidence of surgical site infections recorded during postoperative hospital stay.

    Time frame: up to 2 weeks

07

Study locations

1 site
  • Gazi University
    Ankara, 06560, Turkey (Türkiye)
08

References and documents

Publications

  • Saracoglu A, Yamansavci Sirzai E, Yildizeli B, Yuksel M, Aykac ZZ. Oxygen reserve index guided oxygen titration in one lung ventilation with low fresh gas flow. Turk J Med Sci. 2021 Oct 21;51(5):2413-2419. doi: 10.3906/sag-2009-149. PubMed 34051711 ↗
  • Aykenar B, Ayhan A, Issi S, Kilic MD, Zeyneloglu P. Effects of FiO2 adjustment on hyperoxia biomarkers and postoperative complications using oxygen reserve index during one-lung ventilation. BMC Anesthesiol. 2026 Jun 15. doi: 10.1186/s12871-026-04020-6. Online ahead of print. PubMed 42289654 ↗

Individual participant data

Plan to share: No — The data generated during this study may be made available for use in future meta-analyses upon reasonable request to the corresponding author.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2023, 11 months.

Of 37 non-industry interventional studies with no phase under Hyperoxia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's 11 months is below that.

Counting every sponsor, half of 39 studies reached it within 12 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2026
First posted
Jan 22, 2026
StartActual
Aug 5, 2022
Primary completionActual
Jul 15, 2023
CompletionActual
Aug 30, 2023
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359833
Lead sponsor
Gazi University
Responsible party
Bugra AYKENAR (Anesthesia resident, Gazi University) — Principal investigator
First posted
Jan 22, 2026
Start date
Aug 5, 2022
Primary completion
Jul 15, 2023
Completion
Aug 30, 2023
Last update
Jan 22, 2026

Study contacts

Buğra Aykenar
principal investigator · Gazi University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion